

# Enhanced stent visualization impact on older MI patients with multivessel disease

#### **Marta Cocco**

Ferrara University Hospital, Italy







#### Potential conflicts of interest

#### **Speaker's name: Marta Cocco**

✓ I do not have any potential conflict of interest to declare.


Unrestrected research grants for the conduction of the FIRE trial by Sahajanand Medical Technologies, Medis Medical Imaging Systems, Eukon, Siemens Healthineers, General Electric Healthcare and Insight Lifetech.



## Background

## **Enhanced Stent Visualization (ESV)**

- ✓ High-quality real-time enhanced stent visualization during and after stent positioning.
- ✓ Assessment of stent integrity and/or stent underdexpansion, gap assessment.
- ✓ Improved stent characterisation versus coronary angiography alone and good correlation with IVUS for stent underexpansion.
- ✓ Alternatively or complementary to more complex intracoronary imaging techniques (IVUS or OCT).





## Background

## The CLASSY-FIRE is a prespecified substudy of the



75+ AMI pts with MVD (n=1445)

Successfull PCI of the culprit lesion

Cruz




Physio-guided complete arm (n= 720)

Culprit-only arm (n= 725)



On top of a deemed successful PCI

ESV-guided optimization (n = 331)







## **Objectives**


- To evaluate the rate of post-PCI ESV findings prompting further procedural optimization.
- To assess the minimal lumen diameter (MLD) acute gain after ESV-guided optimization.
- To compare the rate of events between patients who underwent an ESV-guided PCI versus angio-guided PCI.




## How was the study executed?

Recording of any procedural optimization after ESV















QCA MLD calculation pre and post ESV optimization

## Primary Endpoint


VOCE (vessel-oriented composite endpoint) at 1 year: composite of cardiac death, target-vessel MI or ischemia-driven TVR





## What are the essential results?


	Patients (n = 1445)		
Characteristic	ESV-guided PCI (n=331)	Angio-guided PCI (n=1114)	р
Age – years	81±4	81±4	0.993
Female – no. (%)	120 (36.2)	408 (36.6)	0.933
Diabetes – no. (%)	100 (30.2)	363 (32.6)	0.557
Prior PCI – no. (%)	61 (18.4)	196 (17.6)	0.771
PAD – no (%)	79 (23.8)	170 (15.2)	0.002
STEMI – no. (%)	87 (26.3)	422 (37.8)	0.005
NSTEMI – no. (%)	244 (73.7)	692 (62.2)	
LAD	152 (45.9)	501 (45.0)	0.802
LCX	60 (18.1)	200 (17.9)	0.765
LM	34 (10.3)	44 (3.9)	0.032
RCA	78 (23.6)	346 (31.1)	0.152
RI	7 (2.1)	23 (2.0)	0.821






## What are the essential results?











## What are the essential results?

#### **Post-dilation rate**



VOCE (vessel-oriented composite endpoint) at 1 year: composite of cardiac death, target-vessel MI or ischemia-driven TVR





## **Conclusions**

- > PCI optimization through imaging and/or physiology is impactful on prognosis but still largely underused.
- ESV use during complex PCI triggers procedural optimization, significantly increasing the post-dilation rate, as compare to the ESV negative group.
- ➤ ESV-driven PCI optimization leads to a significant acute MLD gain and reduction of VOCE at 1 year
- **ESV** could represent a simple and easy gatekeeper for imaging or further procedural optimization.



### The essentials to remember

Why?

Intracoronary imaging use for PCI optimization is largely underused, especially in older patients.

What?

To investigate the impact of ESV use on AMI patients of the FIRE trial

How?

What are the results?

By recording ESV-triggered procedural optimizations, MLD acute gain and VOCE at 1 year.

Post-dilation rate is significantly higher in the ESV + group and is associated with significant acute MLD gain and reduction of VOCE at 1 year.

Why is this important?

CLASSY FIRE substudy provides evidence supporting the use of ESV during complex PCI as a simple and easy gatekeeper for imaging or further procedural optimization.



PCRonline.com